AustralieFrV1, PubMed, Checkpoint, bibRecord, 003515

HDL-targeted therapies: progress, failures and future.

Identifieur interne : 003515 ( PubMed/Checkpoint ); précédent : 003514; suivant : 003516

HDL-targeted therapies: progress, failures and future.

Auteurs : Bronwyn A. Kingwell [Australie] ; M John Chapman [France] ; Anatol Kontush [France] ; Norman E. Miller [Royaume-Uni]

Source :

Nature reviews. Drug discovery [ 1474-1784 ] ; 2014.

RBID : pubmed:24854407

Descripteurs français

KwdFr :
- Acide nicotinique (effets indésirables), Acide nicotinique (métabolisme), Acide nicotinique (usage thérapeutique), Animaux, Apolipoprotéine A-I (agonistes), Apolipoprotéine A-I (génétique), Apolipoprotéine A-I (métabolisme), Essais cliniques comme sujet, Humains, Hypolipémiants (effets indésirables), Hypolipémiants (métabolisme), Hypolipémiants (usage thérapeutique), Lipoprotéines HDL (agonistes), Lipoprotéines HDL (métabolisme), Lipoprotéines HDL (sang), Lipoprotéines HDL (usage thérapeutique), Maladies cardiovasculaires (), Maladies cardiovasculaires (métabolisme), Maladies cardiovasculaires (sang), Modèles biologiques, Médicaments en essais cliniques (effets indésirables), Médicaments en essais cliniques (métabolisme), Médicaments en essais cliniques (usage thérapeutique), Phosphatidylcholine-Sterol O-Acyltransferase (effets indésirables), Phosphatidylcholine-Sterol O-Acyltransferase (génétique), Phosphatidylcholine-Sterol O-Acyltransferase (métabolisme), Phosphatidylcholine-Sterol O-Acyltransferase (usage thérapeutique), Protéines de transfert des esters de cholestérol (antagonistes et inhibiteurs), Protéines de transfert des esters de cholestérol (métabolisme), Protéines recombinantes (effets indésirables), Protéines recombinantes (métabolisme), Protéines recombinantes (usage thérapeutique), Régulation positive (), Thérapie moléculaire ciblée (effets indésirables).
MESH :
- agonistes : Apolipoprotéine A-I, Lipoprotéines HDL.
- antagonistes et inhibiteurs : Protéines de transfert des esters de cholestérol.
- effets indésirables : Acide nicotinique, Hypolipémiants, Médicaments en essais cliniques, Phosphatidylcholine-Sterol O-Acyltransferase, Protéines recombinantes, Thérapie moléculaire ciblée.
- génétique : Apolipoprotéine A-I, Phosphatidylcholine-Sterol O-Acyltransferase.
- métabolisme : Acide nicotinique, Apolipoprotéine A-I, Hypolipémiants, Lipoprotéines HDL, Maladies cardiovasculaires, Médicaments en essais cliniques, Phosphatidylcholine-Sterol O-Acyltransferase, Protéines de transfert des esters de cholestérol, Protéines recombinantes.
- sang : Lipoprotéines HDL, Maladies cardiovasculaires.
- usage thérapeutique : Acide nicotinique, Hypolipémiants, Lipoprotéines HDL, Médicaments en essais cliniques, Phosphatidylcholine-Sterol O-Acyltransferase, Protéines recombinantes.
- Animaux, Essais cliniques comme sujet, Humains, Maladies cardiovasculaires, Modèles biologiques, Régulation positive.

English descriptors

KwdEn :
- Animals, Apolipoprotein A-I (agonists), Apolipoprotein A-I (genetics), Apolipoprotein A-I (metabolism), Cardiovascular Diseases (blood), Cardiovascular Diseases (metabolism), Cardiovascular Diseases (prevention & control), Cholesterol Ester Transfer Proteins (antagonists & inhibitors), Cholesterol Ester Transfer Proteins (metabolism), Clinical Trials as Topic, Drugs, Investigational (adverse effects), Drugs, Investigational (metabolism), Drugs, Investigational (therapeutic use), Humans, Hypolipidemic Agents (adverse effects), Hypolipidemic Agents (metabolism), Hypolipidemic Agents (therapeutic use), Lipoproteins, HDL (agonists), Lipoproteins, HDL (blood), Lipoproteins, HDL (metabolism), Lipoproteins, HDL (therapeutic use), Models, Biological, Molecular Targeted Therapy (adverse effects), Niacin (adverse effects), Niacin (metabolism), Niacin (therapeutic use), Phosphatidylcholine-Sterol O-Acyltransferase (adverse effects), Phosphatidylcholine-Sterol O-Acyltransferase (genetics), Phosphatidylcholine-Sterol O-Acyltransferase (metabolism), Phosphatidylcholine-Sterol O-Acyltransferase (therapeutic use), Recombinant Proteins (adverse effects), Recombinant Proteins (metabolism), Recombinant Proteins (therapeutic use), Up-Regulation (drug effects).
MESH :
- chemical , adverse effects : Drugs, Investigational, Hypolipidemic Agents, Niacin, Phosphatidylcholine-Sterol O-Acyltransferase, Recombinant Proteins.
- chemical , agonists : Apolipoprotein A-I, Lipoproteins, HDL.
- chemical , antagonists & inhibitors : Cholesterol Ester Transfer Proteins.
- chemical , blood : Lipoproteins, HDL.
- chemical , genetics : Apolipoprotein A-I, Phosphatidylcholine-Sterol O-Acyltransferase.
- chemical , metabolism : Apolipoprotein A-I, Cholesterol Ester Transfer Proteins, Drugs, Investigational, Hypolipidemic Agents, Lipoproteins, HDL, Niacin, Phosphatidylcholine-Sterol O-Acyltransferase, Recombinant Proteins.
- adverse effects : Molecular Targeted Therapy.
- blood : Cardiovascular Diseases.
- drug effects : Up-Regulation.
- metabolism : Cardiovascular Diseases.
- prevention & control : Cardiovascular Diseases.
- chemical , therapeutic use : Drugs, Investigational, Hypolipidemic Agents, Lipoproteins, HDL, Niacin, Phosphatidylcholine-Sterol O-Acyltransferase, Recombinant Proteins.
- Animals, Clinical Trials as Topic, Humans, Models, Biological.

Abstract

Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that HDL is anti-atherogenic and that increasing HDL-C levels is a promising therapeutic strategy. However, the recent failure of three orally active, HDL-C-raising agents has introduced considerable controversy, prompting the question of whether increasing the cholesterol cargo of HDL in a non-selective manner is an effective pharmacological approach for the translation of its atheroprotective and vasculoprotective activities. The interrelationships between HDL-C concentration, HDL particle number and levels of diverse HDL particle subpopulations of defined composition are complex, as are their relationships with reverse cholesterol transport and other anti-atherogenic functions. Such complexity highlights the incompleteness of our understanding of the biology of HDL particles. This article examines the HDL hypothesis in molecular and mechanistic terms, focusing on features that have been addressed, those that remain to be tested, and potential new targets for future pharmacological interventions.

DOI: 10.1038/nrd4279
PubMed: 24854407

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003701
to stream PubMed, to step Curation: 003587

Links to Exploration step

pubmed:24854407

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HDL-targeted therapies: progress, failures and future.</title>
<author><name sortKey="Kingwell, Bronwyn A" sort="Kingwell, Bronwyn A" uniqKey="Kingwell B" first="Bronwyn A" last="Kingwell">Bronwyn A. Kingwell</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004</wicri:regionArea>
<wicri:noRegion>Victoria 3004</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name>
<affiliation wicri:level="4"><nlm:affiliation>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6</wicri:regionArea>
<wicri:noRegion>Paris 6</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Pierre-et-Marie-Curie</orgName>
</affiliation>
</author>
<author><name sortKey="Kontush, Anatol" sort="Kontush, Anatol" uniqKey="Kontush A" first="Anatol" last="Kontush">Anatol Kontush</name>
<affiliation wicri:level="4"><nlm:affiliation>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6</wicri:regionArea>
<wicri:noRegion>Paris 6</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Pierre-et-Marie-Curie</orgName>
</affiliation>
</author>
<author><name sortKey="Miller, Norman E" sort="Miller, Norman E" uniqKey="Miller N" first="Norman E" last="Miller">Norman E. Miller</name>
<affiliation wicri:level="4"><nlm:affiliation>Magdalen College, University of Oxford, Oxford OX1 4AU, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Magdalen College, University of Oxford, Oxford OX1 4AU</wicri:regionArea>
<orgName type="university">Université d'Oxford</orgName>
<placeName><settlement type="city">Oxford</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Oxfordshire</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24854407</idno>
<idno type="pmid">24854407</idno>
<idno type="doi">10.1038/nrd4279</idno>
<idno type="wicri:Area/PubMed/Corpus">003701</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003701</idno>
<idno type="wicri:Area/PubMed/Curation">003587</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003587</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003587</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003587</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">HDL-targeted therapies: progress, failures and future.</title>
<author><name sortKey="Kingwell, Bronwyn A" sort="Kingwell, Bronwyn A" uniqKey="Kingwell B" first="Bronwyn A" last="Kingwell">Bronwyn A. Kingwell</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004</wicri:regionArea>
<wicri:noRegion>Victoria 3004</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name>
<affiliation wicri:level="4"><nlm:affiliation>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6</wicri:regionArea>
<wicri:noRegion>Paris 6</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Pierre-et-Marie-Curie</orgName>
</affiliation>
</author>
<author><name sortKey="Kontush, Anatol" sort="Kontush, Anatol" uniqKey="Kontush A" first="Anatol" last="Kontush">Anatol Kontush</name>
<affiliation wicri:level="4"><nlm:affiliation>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6</wicri:regionArea>
<wicri:noRegion>Paris 6</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Pierre-et-Marie-Curie</orgName>
</affiliation>
</author>
<author><name sortKey="Miller, Norman E" sort="Miller, Norman E" uniqKey="Miller N" first="Norman E" last="Miller">Norman E. Miller</name>
<affiliation wicri:level="4"><nlm:affiliation>Magdalen College, University of Oxford, Oxford OX1 4AU, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Magdalen College, University of Oxford, Oxford OX1 4AU</wicri:regionArea>
<orgName type="university">Université d'Oxford</orgName>
<placeName><settlement type="city">Oxford</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Oxfordshire</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature reviews. Drug discovery</title>
<idno type="eISSN">1474-1784</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Apolipoprotein A-I (agonists)</term>
<term>Apolipoprotein A-I (genetics)</term>
<term>Apolipoprotein A-I (metabolism)</term>
<term>Cardiovascular Diseases (blood)</term>
<term>Cardiovascular Diseases (metabolism)</term>
<term>Cardiovascular Diseases (prevention & control)</term>
<term>Cholesterol Ester Transfer Proteins (antagonists & inhibitors)</term>
<term>Cholesterol Ester Transfer Proteins (metabolism)</term>
<term>Clinical Trials as Topic</term>
<term>Drugs, Investigational (adverse effects)</term>
<term>Drugs, Investigational (metabolism)</term>
<term>Drugs, Investigational (therapeutic use)</term>
<term>Humans</term>
<term>Hypolipidemic Agents (adverse effects)</term>
<term>Hypolipidemic Agents (metabolism)</term>
<term>Hypolipidemic Agents (therapeutic use)</term>
<term>Lipoproteins, HDL (agonists)</term>
<term>Lipoproteins, HDL (blood)</term>
<term>Lipoproteins, HDL (metabolism)</term>
<term>Lipoproteins, HDL (therapeutic use)</term>
<term>Models, Biological</term>
<term>Molecular Targeted Therapy (adverse effects)</term>
<term>Niacin (adverse effects)</term>
<term>Niacin (metabolism)</term>
<term>Niacin (therapeutic use)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (adverse effects)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (genetics)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (metabolism)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (therapeutic use)</term>
<term>Recombinant Proteins (adverse effects)</term>
<term>Recombinant Proteins (metabolism)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Up-Regulation (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide nicotinique (effets indésirables)</term>
<term>Acide nicotinique (métabolisme)</term>
<term>Acide nicotinique (usage thérapeutique)</term>
<term>Animaux</term>
<term>Apolipoprotéine A-I (agonistes)</term>
<term>Apolipoprotéine A-I (génétique)</term>
<term>Apolipoprotéine A-I (métabolisme)</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Hypolipémiants (effets indésirables)</term>
<term>Hypolipémiants (métabolisme)</term>
<term>Hypolipémiants (usage thérapeutique)</term>
<term>Lipoprotéines HDL (agonistes)</term>
<term>Lipoprotéines HDL (métabolisme)</term>
<term>Lipoprotéines HDL (sang)</term>
<term>Lipoprotéines HDL (usage thérapeutique)</term>
<term>Maladies cardiovasculaires ()</term>
<term>Maladies cardiovasculaires (métabolisme)</term>
<term>Maladies cardiovasculaires (sang)</term>
<term>Modèles biologiques</term>
<term>Médicaments en essais cliniques (effets indésirables)</term>
<term>Médicaments en essais cliniques (métabolisme)</term>
<term>Médicaments en essais cliniques (usage thérapeutique)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (effets indésirables)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (génétique)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (métabolisme)</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase (usage thérapeutique)</term>
<term>Protéines de transfert des esters de cholestérol (antagonistes et inhibiteurs)</term>
<term>Protéines de transfert des esters de cholestérol (métabolisme)</term>
<term>Protéines recombinantes (effets indésirables)</term>
<term>Protéines recombinantes (métabolisme)</term>
<term>Protéines recombinantes (usage thérapeutique)</term>
<term>Régulation positive ()</term>
<term>Thérapie moléculaire ciblée (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Drugs, Investigational</term>
<term>Hypolipidemic Agents</term>
<term>Niacin</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Apolipoprotein A-I</term>
<term>Lipoproteins, HDL</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cholesterol Ester Transfer Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Lipoproteins, HDL</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Apolipoprotein A-I</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Apolipoprotein A-I</term>
<term>Cholesterol Ester Transfer Proteins</term>
<term>Drugs, Investigational</term>
<term>Hypolipidemic Agents</term>
<term>Lipoproteins, HDL</term>
<term>Niacin</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Apolipoprotéine A-I</term>
<term>Lipoprotéines HDL</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines de transfert des esters de cholestérol</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Up-Regulation</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acide nicotinique</term>
<term>Hypolipémiants</term>
<term>Médicaments en essais cliniques</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
<term>Protéines recombinantes</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Apolipoprotéine A-I</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Acide nicotinique</term>
<term>Apolipoprotéine A-I</term>
<term>Hypolipémiants</term>
<term>Lipoprotéines HDL</term>
<term>Maladies cardiovasculaires</term>
<term>Médicaments en essais cliniques</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
<term>Protéines de transfert des esters de cholestérol</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Lipoprotéines HDL</term>
<term>Maladies cardiovasculaires</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Drugs, Investigational</term>
<term>Hypolipidemic Agents</term>
<term>Lipoproteins, HDL</term>
<term>Niacin</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide nicotinique</term>
<term>Hypolipémiants</term>
<term>Lipoprotéines HDL</term>
<term>Médicaments en essais cliniques</term>
<term>Phosphatidylcholine-Sterol O-Acyltransferase</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Models, Biological</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Maladies cardiovasculaires</term>
<term>Modèles biologiques</term>
<term>Régulation positive</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that HDL is anti-atherogenic and that increasing HDL-C levels is a promising therapeutic strategy. However, the recent failure of three orally active, HDL-C-raising agents has introduced considerable controversy, prompting the question of whether increasing the cholesterol cargo of HDL in a non-selective manner is an effective pharmacological approach for the translation of its atheroprotective and vasculoprotective activities. The interrelationships between HDL-C concentration, HDL particle number and levels of diverse HDL particle subpopulations of defined composition are complex, as are their relationships with reverse cholesterol transport and other anti-atherogenic functions. Such complexity highlights the incompleteness of our understanding of the biology of HDL particles. This article examines the HDL hypothesis in molecular and mechanistic terms, focusing on features that have been addressed, those that remain to be tested, and potential new targets for future pharmacological interventions.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24854407</PMID>
<DateCreated><Year>2014</Year>
<Month>05</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>08</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>06</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>6</Issue>
<PubDate><Year>2014</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Drug discovery</Title>
<ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>
</Journal>
<ArticleTitle>HDL-targeted therapies: progress, failures and future.</ArticleTitle>
<Pagination><MedlinePgn>445-64</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrd4279</ELocationID>
<Abstract><AbstractText>Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that HDL is anti-atherogenic and that increasing HDL-C levels is a promising therapeutic strategy. However, the recent failure of three orally active, HDL-C-raising agents has introduced considerable controversy, prompting the question of whether increasing the cholesterol cargo of HDL in a non-selective manner is an effective pharmacological approach for the translation of its atheroprotective and vasculoprotective activities. The interrelationships between HDL-C concentration, HDL particle number and levels of diverse HDL particle subpopulations of defined composition are complex, as are their relationships with reverse cholesterol transport and other anti-atherogenic functions. Such complexity highlights the incompleteness of our understanding of the biology of HDL particles. This article examines the HDL hypothesis in molecular and mechanistic terms, focusing on features that have been addressed, those that remain to be tested, and potential new targets for future pharmacological interventions.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kingwell</LastName>
<ForeName>Bronwyn A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chapman</LastName>
<ForeName>M John</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kontush</LastName>
<ForeName>Anatol</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>INSERM UMRS-939, Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpetriere Hospital, Université Pierre et Marie Curie, Paris 6, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Miller</LastName>
<ForeName>Norman E</ForeName>
<Initials>NE</Initials>
<AffiliationInfo><Affiliation>Magdalen College, University of Oxford, Oxford OX1 4AU, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>05</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Rev Drug Discov</MedlineTA>
<NlmUniqueID>101124171</NlmUniqueID>
<ISSNLinking>1474-1776</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505693">APOA1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506642">CETP protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053480">Cholesterol Ester Transfer Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2679MF687A</RegistryNumber>
<NameOfSubstance UI="D009525">Niacin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.3.1.43</RegistryNumber>
<NameOfSubstance UI="D007862">Phosphatidylcholine-Sterol O-Acyltransferase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2011 Nov 16;306(19):2099-109</RefSource>
<PMID Version="1">22089718</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1999 Dec 24;274(52):36912-20</RefSource>
<PMID Version="1">10601244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1995 Dec;96(6):2758-67</RefSource>
<PMID Version="1">8675645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Cell Biol. 2011 Apr;13(4):423-33</RefSource>
<PMID Version="1">21423178</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem Lett. 2009 Jan 1;19(1):27-30</RefSource>
<PMID Version="1">19058966</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2014 Jan 3;114(1):205-13</RefSource>
<PMID Version="1">24385513</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2012 Feb;22(2):95-104</RefSource>
<PMID Version="1">22143414</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cholesterol. 2013;2013:891403</RefSource>
<PMID Version="1">23781332</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):979-89</RefSource>
<PMID Version="1">10195926</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1994 Jul;35(7):1187-99</RefSource>
<PMID Version="1">7964180</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2012 Aug 7;60(6):517-20</RefSource>
<PMID Version="1">22796252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Res. 2008 Mar 1;77(4):732-9</RefSource>
<PMID Version="1">18056760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Endocrinol Metab. 2013 Feb 1;304(3):E321-8</RefSource>
<PMID Version="1">23233540</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2007 Apr;28(8):1012-8</RefSource>
<PMID Version="1">17409111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2011 Jul;121(7):2921-31</RefSource>
<PMID Version="1">21646721</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2007 Sep 11;116(11):1267-73</RefSource>
<PMID Version="1">17709636</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1203-15</RefSource>
<PMID Version="1">18939908</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2010 Jun;51(6):1546-53</RefSource>
<PMID Version="1">19965573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Cardiol. 2011 Aug 1;108(3):360-6</RefSource>
<PMID Version="1">21757044</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1990 Nov 1;323(18):1234-8</RefSource>
<PMID Version="1">2215607</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Cardiovasc Med. 2008 Feb;18(2):61-6</RefSource>
<PMID Version="1">18308197</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2715-23</RefSource>
<PMID Version="1">24092747</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2006 May;116(5):1435-42</RefSource>
<PMID Version="1">16670775</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Biol Rep. 2013 Feb;40(2):1997-2014</RefSource>
<PMID Version="1">23129316</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2552-9</RefSource>
<PMID Version="1">16946130</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2012 Mar;33(5):657-65</RefSource>
<PMID Version="1">21498847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1198-200</RefSource>
<PMID Version="1">16709952</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2012 Sep;53(9):1783-99</RefSource>
<PMID Version="1">22566575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2013 Sep 17;128(12):1298-309</RefSource>
<PMID Version="1">23926208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Dec 15;365(24):2255-67</RefSource>
<PMID Version="1">22085343</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2012 Aug 7;60(6):508-16</RefSource>
<PMID Version="1">22796256</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Endocrinol. 2012 Jan 24;8(4):237-45</RefSource>
<PMID Version="1">22271188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cell Mol Med. 2009 Sep;13(9B):3226-35</RefSource>
<PMID Version="1">19120689</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2011 Mar;52(3):572-81</RefSource>
<PMID Version="1">21224289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2000 Jul 13;406(6792):203-7</RefSource>
<PMID Version="1">10910363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 1988 Jan 12;27(1):25-9</RefSource>
<PMID Version="1">3126809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2004 Sep 14;110(11):1418-23</RefSource>
<PMID Version="1">15337694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2010 Jun 18;328(5985):1570-3</RefSource>
<PMID Version="1">20466885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2009 Apr;94(4):1264-73</RefSource>
<PMID Version="1">19088157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2012 Apr 17;125(15):1905-19</RefSource>
<PMID Version="1">22508840</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):158-66</RefSource>
<PMID Version="1">20208032</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 Mar;34(10):719-28</RefSource>
<PMID Version="1">23242196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2001 Sep 4;104(10):1108-13</RefSource>
<PMID Version="1">11535564</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2006 Aug 15;48(4):715-20</RefSource>
<PMID Version="1">16904539</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2008 Jun;51(6):1081-4</RefSource>
<PMID Version="1">18389214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2013 May;19(5):586-94</RefSource>
<PMID Version="1">23584088</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2012 Mar 6;125(9):1147-56</RefSource>
<PMID Version="1">22392862</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2007 Apr 18;297(15):1675-82</RefSource>
<PMID Version="1">17387133</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2011 Jul;32(14):1769-818</RefSource>
<PMID Version="1">21712404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2011 Jun;32(11):1345-61</RefSource>
<PMID Version="1">21531743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 May 29;375(9729):1875-84</RefSource>
<PMID Version="1">20462635</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2006 Nov 10;99(10):1031-43</RefSource>
<PMID Version="1">17095732</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1993 Jul 1;364(6432):73-5</RefSource>
<PMID Version="1">8316302</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Drugs Ther. 2012 Apr;26(2):181-7</RefSource>
<PMID Version="1">22349989</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 1996 Apr;42(4):507-14</RefSource>
<PMID Version="1">8605666</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Intern Med. 2006 Aug;260(2):151-9</RefSource>
<PMID Version="1">16882279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2013 Sep 10;128(11):1189-97</RefSource>
<PMID Version="1">24002795</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2013 Sep 10;128(11):1256-67</RefSource>
<PMID Version="1">24019446</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2011 Jul;217(1):249-52</RefSource>
<PMID Version="1">21524747</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Sci (Lond). 2002 Dec;103(6):587-94</RefSource>
<PMID Version="1">12444911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2002 Mar 26;105(12):1399-402</RefSource>
<PMID Version="1">11914243</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1995 May;36(5):1058-65</RefSource>
<PMID Version="1">7658153</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2008 Feb 12;117(6):743-53</RefSource>
<PMID Version="1">18212285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2341-9</RefSource>
<PMID Version="1">22904275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2008 Jun 18;299(23):2777-88</RefSource>
<PMID Version="1">18560005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JACC Cardiovasc Imaging. 2012 Feb;5(2):169-77</RefSource>
<PMID Version="1">22340823</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2014 Feb;20(2):193-203</RefSource>
<PMID Version="1">24464187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2002 Dec 17;106(25):3143-421</RefSource>
<PMID Version="1">12485966</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Invest. 2010 Jul;40(7):616-22</RefSource>
<PMID Version="1">20497463</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2013 Jan 29;61(4):440-6</RefSource>
<PMID Version="1">23265337</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1996 Jun 15;97(12):2917-23</RefSource>
<PMID Version="1">8675707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1653-9</RefSource>
<PMID Version="1">12893687</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2012 Dec;343(3):556-67</RefSource>
<PMID Version="1">22918042</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2010 Jun 15;55(24):2727-35</RefSource>
<PMID Version="1">20538165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Nov 22;357(21):2109-22</RefSource>
<PMID Version="1">17984165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2010 Nov;51(11):3243-9</RefSource>
<PMID Version="1">20713652</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2014 Jan 3;114(1):124-42</RefSource>
<PMID Version="1">24385507</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):565-71</RefSource>
<PMID Version="1">23307871</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2013 Apr;227(2):201-8</RefSource>
<PMID Version="1">23261171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2007 Feb 7;297(5):499-508</RefSource>
<PMID Version="1">17284700</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2003 Apr 1;107(12):1640-6</RefSource>
<PMID Version="1">12668499</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2008 Jan-Feb;1781(1-2):10-5</RefSource>
<PMID Version="1">18178167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2009 Feb;157(2):352-360.e2</RefSource>
<PMID Version="1">19185645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1672-8</RefSource>
<PMID Version="1">18566298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2009 Aug;205(2):413-9</RefSource>
<PMID Version="1">19201410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2008 Nov;29(22):2792-9</RefSource>
<PMID Version="1">18957472</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2010 Jul;56(7):1128-37</RefSource>
<PMID Version="1">20511449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2007 Nov;195(1):122-8</RefSource>
<PMID Version="1">17011566</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 Jan;34(4):286-91</RefSource>
<PMID Version="1">23136402</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Metab. 2013 Aug 6;18(2):225-38</RefSource>
<PMID Version="1">23931754</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1996 Jun 15;97(12):2687-8</RefSource>
<PMID Version="1">8675675</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2012 Nov 13;60(20):2049-52</RefSource>
<PMID Version="1">23083775</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2003 Jun 17;107(23):2944-8</RefSource>
<PMID Version="1">12771001</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>APMIS. 1997 Nov;105(11):861-8</RefSource>
<PMID Version="1">9393557</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1912-7</RefSource>
<PMID Version="1">12426224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2014 Jan 3;114(1):143-56</RefSource>
<PMID Version="1">24385508</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin Lipidol. 2011 Apr;22(2):113-22</RefSource>
<PMID Version="1">21358543</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 1995 Jan 17;748:606-8</RefSource>
<PMID Version="1">7695214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1975 Jan 4;1(7897):16-9</RefSource>
<PMID Version="1">46338</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Atheroscler Rep. 2011 Feb;13(1):81-7</RefSource>
<PMID Version="1">21057986</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 May;34(17 ):1279-91</RefSource>
<PMID Version="1">23444397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2015 Mar 1;36(9):539-50</RefSource>
<PMID Version="1">24474739</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2012 May 22;125(20):2469-78</RefSource>
<PMID Version="1">22539783</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jan 13;364(2):127-35</RefSource>
<PMID Version="1">21226578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Apr 29;362(17):1563-74</RefSource>
<PMID Version="1">20228404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):897-902</RefSource>
<PMID Version="1">16469947</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2008 Sep;200(1):161-7</RefSource>
<PMID Version="1">18164013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2001 Apr;42(4):639-48</RefSource>
<PMID Version="1">11290836</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Heart Assoc. 2012 Dec;1(6):e003376</RefSource>
<PMID Version="1">23316322</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1843-9</RefSource>
<PMID Version="1">17569880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2006 Mar 7;47(5):992-7</RefSource>
<PMID Version="1">16516083</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1642-8</RefSource>
<PMID Version="1">20466975</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1995 Oct;96(4):2071-4</RefSource>
<PMID Version="1">7560101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 1977 May;55(5):767-72</RefSource>
<PMID Version="1">191215</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2009 Feb;50(2):301-11</RefSource>
<PMID Version="1">18757914</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2005 Jun 24;96(12 ):1221-32</RefSource>
<PMID Version="1">15976321</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Nov 29;367(22):2089-99</RefSource>
<PMID Version="1">23126252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 2006 Sep;58(3):342-74</RefSource>
<PMID Version="1">16968945</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Biol Sci. 2009 Jul 28;5(5):489-99</RefSource>
<PMID Version="1">19680471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S42-52</RefSource>
<PMID Version="1">22421230</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2011 Oct 19;478(7369):404-7</RefSource>
<PMID Version="1">22012398</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Invest. 1978 Jun;8(3):179-82</RefSource>
<PMID Version="1">99314</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2010 Oct;335(1):140-8</RefSource>
<PMID Version="1">20605907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1993 Aug;34(8):1255-74</RefSource>
<PMID Version="1">8409761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2010 Jun 18;328(5985):1566-9</RefSource>
<PMID Version="1">20466882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 1997 Jul;3(7):744-9</RefSource>
<PMID Version="1">9212100</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Ther. 2008 Winter;26(4):297-316</RefSource>
<PMID Version="1">19035881</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7166-71</RefSource>
<PMID Version="1">21482781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):39-46</RefSource>
<PMID Version="1">17717290</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 May 8;375(9726):1634-9</RefSource>
<PMID Version="1">20452521</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2004 Mar;50(3):589-95</RefSource>
<PMID Version="1">14726473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2004 Aug;20(8):1253-68</RefSource>
<PMID Version="1">15324528</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1430-8</RefSource>
<PMID Version="1">20448206</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1996 Jun;37(6):1268-77</RefSource>
<PMID Version="1">8808761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2010 Jan 26;121(3):366-74</RefSource>
<PMID Version="1">20065167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2000 Jul 4;102(1):21-7</RefSource>
<PMID Version="1">10880410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Aug 11;380(9841):572-80</RefSource>
<PMID Version="1">22607825</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 1993 Jun 8;32(22):5759-65</RefSource>
<PMID Version="1">8504094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1995 Dec;96(6):2613-22</RefSource>
<PMID Version="1">8675626</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cell Mol Med. 2010 Jan;14(1-2):79-92</RefSource>
<PMID Version="1">20041971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2009 Apr 21;119(15):2103-11</RefSource>
<PMID Version="1">19349317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics. 2008 Jun;9(6):747-63</RefSource>
<PMID Version="1">18518852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2006 Mar 28;113(12):1556-63</RefSource>
<PMID Version="1">16534013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Cardiol. 2010 Aug 15;106(4):451-6</RefSource>
<PMID Version="1">20691300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2012 Nov;30(11):1095-106</RefSource>
<PMID Version="1">23138309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2009 Mar 17;53(11):962-71</RefSource>
<PMID Version="1">19281927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1325-31</RefSource>
<PMID Version="1">15831812</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2001 Mar 28;285(12):1585-91</RefSource>
<PMID Version="1">11268266</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem Lett. 2012 Feb 1;22(3):1397-401</RefSource>
<PMID Version="1">22225633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2009 Apr;50 Suppl:S195-200</RefSource>
<PMID Version="1">19033213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2011 Mar;57(3):392-410</RefSource>
<PMID Version="1">21266551</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Invest. 2007 Dec;37(12):925-32</RefSource>
<PMID Version="1">18036028</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2011 Jul;121(7):2693-708</RefSource>
<PMID Version="1">21701070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2004 Sep 11-17;364(9438):937-52</RefSource>
<PMID Version="1">15364185</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1849-56</RefSource>
<PMID Version="1">7583564</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2012 Mar;163(3):515-21, 521.e1-3</RefSource>
<PMID Version="1">22424025</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Biol Sci. 2009 Oct 09;5(7):637-46</RefSource>
<PMID Version="1">19847320</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2002 Feb 1;277(5):3511-9</RefSource>
<PMID Version="1">11719520</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2003 Nov 5;290(17 ):2292-300</RefSource>
<PMID Version="1">14600188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12176-81</RefSource>
<PMID Version="1">18719128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cell Mol Med. 2010 Mar;14(3):608-20</RefSource>
<PMID Version="1">19243471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 1956 Nov 16;64(4):590-5</RefSource>
<PMID Version="1">13373230</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Jul 19;372(9634):224-33</RefSource>
<PMID Version="1">18640459</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Shock. 2008 Nov;30(5):590-5</RefSource>
<PMID Version="1">18391856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Clin Pract Cardiovasc Med. 2006 Mar;3(3):144-53</RefSource>
<PMID Version="1">16505860</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1392-400</RefSource>
<PMID Version="1">23559634</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 1996 Jul;124 Suppl:S11-20</RefSource>
<PMID Version="1">8831911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2012 Sep;18(9):1346-7</RefSource>
<PMID Version="1">22961165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2000 Dec;106(12):1501-10</RefSource>
<PMID Version="1">11120757</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 1992 Feb 20;1124(1):52-8</RefSource>
<PMID Version="1">1543725</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2013 May 24;112(11):1479-90</RefSource>
<PMID Version="1">23542898</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2013 Oct;54(10):2647-57</RefSource>
<PMID Version="1">23801661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2013 Jul 5;113(2):167-75</RefSource>
<PMID Version="1">23676183</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2004 Jul;45(7):1169-96</RefSource>
<PMID Version="1">15102878</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 May;34(17 ):1254-7</RefSource>
<PMID Version="1">23444398</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):870-6</RefSource>
<PMID Version="1">19325143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2010 Jun;210(2):353-61</RefSource>
<PMID Version="1">20079494</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2010 Feb;51(2):416-21</RefSource>
<PMID Version="1">19671930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2009 Nov 24;120(21):2095-104</RefSource>
<PMID Version="1">19901191</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2005 May;25(5):1057-64</RefSource>
<PMID Version="1">15761191</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Geriatrics. 1956 Sep;11(9):413-8</RefSource>
<PMID Version="1">13365916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1977 May 7;1(8019):965-8</RefSource>
<PMID Version="1">67464</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2013 Nov;54(11):2950-63</RefSource>
<PMID Version="1">23543772</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2013 Jul 2;62(1):21-9</RefSource>
<PMID Version="1">23644090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2003 Jan 2;421(6918):75-9</RefSource>
<PMID Version="1">12511957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Med. 1951 Oct;11(4):480-93</RefSource>
<PMID Version="1">14885223</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2010 Jun 8;55(23):2580-9</RefSource>
<PMID Version="1">20513599</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2011 Mar 1;57(9):1111-9</RefSource>
<PMID Version="1">21255957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biochem. 1994 Aug;116(2):257-62</RefSource>
<PMID Version="1">7822240</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2000 Feb 8;101(5):477-84</RefSource>
<PMID Version="1">10662743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2002 Nov;165(1):89-100</RefSource>
<PMID Version="1">12208474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Dec 16;363(25):2406-15</RefSource>
<PMID Version="1">21082868</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1994 Mar 2;271(9):672-7</RefSource>
<PMID Version="1">8309029</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 1992 Jan;85(1):37-45</RefSource>
<PMID Version="1">1728471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2013 May;228(1):230-6</RefSource>
<PMID Version="1">23477743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2012 Mar;53(3):540-7</RefSource>
<PMID Version="1">22180633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Mol Med. 2011 Oct;17(10):594-603</RefSource>
<PMID Version="1">21839683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2012 Sep;18(9):1344-6</RefSource>
<PMID Version="1">22961164</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2009 Dec 15;120(24):2414-20</RefSource>
<PMID Version="1">19948972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Cardiol Rep. 2012 Dec;14(6):684-91</RefSource>
<PMID Version="1">22991041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2011 Aug 2;124(5):555-62</RefSource>
<PMID Version="1">21804130</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Epidemiol. 2004 Feb;33(1):30-42</RefSource>
<PMID Version="1">15075143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1995 Feb;36(2):211-28</RefSource>
<PMID Version="1">7751809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2008 Nov 7;103(10):1084-91</RefSource>
<PMID Version="1">18832751</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Metabolism. 1991 Jul;40(7):756-63</RefSource>
<PMID Version="1">1870431</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 1996 Oct 15;94(8):2013-20</RefSource>
<PMID Version="1">8873680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2001 Oct;42(10):1586-93</RefSource>
<PMID Version="1">11590214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem. 2010 Dec 15;18(24):8669-78</RefSource>
<PMID Version="1">21115285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2008 Dec 12;322(5908):1702-5</RefSource>
<PMID Version="1">19074352</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2014 Jan 3;114(1):183-92</RefSource>
<PMID Version="1">24385511</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2010 May;56(5):723-8</RefSource>
<PMID Version="1">20224045</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2012 May;23(5):934-47</RefSource>
<PMID Version="1">22282592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2013 Sep 3;128(10):1112-21</RefSource>
<PMID Version="1">24002713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2000 May;20(5):1323-9</RefSource>
<PMID Version="1">10807749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11</RefSource>
<PMID Version="1">23868939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Ther. 2015 Mar-Apr;22(2):147-58</RefSource>
<PMID Version="1">23567794</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2003 Jun 4;41(11):1990-3</RefSource>
<PMID Version="1">12798570</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName>
<QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053480" MajorTopicYN="N">Cholesterol Ester Transfer Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName>
<QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009525" MajorTopicYN="N">Niacin</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007862" MajorTopicYN="N">Phosphatidylcholine-Sterol O-Acyltransferase</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24854407</ArticleId>
<ArticleId IdType="pii">nrd4279</ArticleId>
<ArticleId IdType="doi">10.1038/nrd4279</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Oxfordshire</li>
<li>Île-de-France</li>
</region>
<settlement><li>Oxford</li>
<li>Paris</li>
</settlement>
<orgName><li>Université Pierre-et-Marie-Curie</li>
<li>Université d'Oxford</li>
</orgName>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Kingwell, Bronwyn A" sort="Kingwell, Bronwyn A" uniqKey="Kingwell B" first="Bronwyn A" last="Kingwell">Bronwyn A. Kingwell</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name>
</region>
<name sortKey="Kontush, Anatol" sort="Kontush, Anatol" uniqKey="Kontush A" first="Anatol" last="Kontush">Anatol Kontush</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Miller, Norman E" sort="Miller, Norman E" uniqKey="Miller N" first="Norman E" last="Miller">Norman E. Miller</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003515 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003515 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24854407
   |texte=   HDL-targeted therapies: progress, failures and future.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24854407" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

HDL-targeted therapies: progress, failures and future.

HDL-targeted therapies: progress, failures and future.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki